​
​

NGM Biopharmaceuticals (NGM) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

NGM Biopharmaceuticals Revenue Highlights

0

Latest Revenue (Q)

$165.00K

NGM Biopharmaceuticals Revenue by Period

NGM Biopharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31--100.00%
2022-12-31$55.33M-28.95%
2021-12-31$77.88M-10.86%
2020-12-31$87.37M-15.62%
2019-12-31$103.54M-4.71%
2018-12-31$108.67M40.87%
2017-12-31$77.14M-9.87%
2016-12-31$85.59M-

NGM Biopharmaceuticals generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

NGM Biopharmaceuticals Revenue by Quarter

DateRevenueChange
2023-12-31$165.00K-71.65%
2023-09-30$582.00K-59.10%
2023-06-30$1.42M-36.67%
2023-03-31$2.25M-87.64%
2022-12-31$18.18M129.82%
2022-09-30$7.91M-4.61%
2022-06-30$8.29M-60.41%
2022-03-31$20.95M-0.05%
2021-12-31$20.96M12.83%
2021-09-30$18.57M10.74%
2021-06-30$16.77M-22.26%
2021-03-31$21.57M9.15%
2020-12-31$19.77M-15.82%
2020-09-30$23.48M18.87%
2020-06-30$19.75M-18.92%
2020-03-31$24.36M-21.62%
2019-12-31$31.08M44.12%
2019-09-30$21.57M-14.89%
2019-06-30$25.34M-0.83%
2019-03-31$25.55M-45.77%
2018-12-31$47.12M126.37%
2018-09-30$20.82M-5.89%
2018-06-30$22.12M18.83%
2018-03-31$18.61M-

NGM Biopharmaceuticals generated $165.00K in revenue during Q4 2023, up -71.65% compared to the previous quarter, and up 2.09% compared to the same period a year ago.

NGM Biopharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
FHTXFoghorn Therapeutics$34.16M$7.81M
ASMBAssembly Biosciences$7.16M$6.84M
KZRKezar Life Sciences$7.00M-
GBIOGeneration Bio$5.90M$4.09M
IPSCCentury Therapeutics$2.23M$791.00K
KROSKeros Therapeutics$151.00K$37.00K
LYELLyell Immunopharma$130.00K$34.00K
RZLTRezolute--
CCCCC4 Therapeutics--
NGMNGM Biopharmaceuticals-$165.00K
NKTXNkarta--
NXTCNextCure--
TILInstil Bio--
ERASErasca--
CYTCyteir Therapeutics--
NLTXNeurogene--
ACHLAchilles Therapeutics--
PRLDPrelude Therapeutics--
MLYSMineralys Therapeutics--
SANASana Bio--
GLUEMonte Rosa Therapeutics-$4.70M

NGM Revenue FAQ

What is NGM Biopharmaceuticals’s yearly revenue?

NGM Biopharmaceuticals's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $55.33M, representing a decrease of -28.95% compared to 2021. NGM's yearly revenue for 2021 was $77.88M, representing a decrease of -10.86% compared to 2020.

What is NGM Biopharmaceuticals’s quarterly revenue?

NGM Biopharmaceuticals's quarterly revenue for Q4 2023 was $165K, a -71.65% decrease from the previous quarter (Q3 2023), and a -99.09% decrease year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $582K, a -59.10% decrease from the previous quarter (Q2 2023), and a -92.64% decrease year-over-year (Q3 2022). NGM's quarterly revenue for Q2 2023 was $1.42M, a -36.67% decrease from the previous quarter (Q1 2023), and a -82.84% decrease year-over-year (Q2 2022).

What is NGM Biopharmaceuticals’s revenue growth rate?

NGM Biopharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.